Frontier Asset Management LLC Takes Position in Abbott Laboratories $ABT

Frontier Asset Management LLC bought a new stake in Abbott Laboratories (NYSE:ABT) in the second quarter, HoldingsChannel.com reports. The firm bought 19,868 shares of the healthcare product maker’s stock, valued at approximately $1,803,000. Abbott Laboratories accounts for 0.3% of Frontier Asset Management LLC’s portfolio, making the stock its 20th biggest position.

Other large investors also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth approximately $25,000. Cornerstone Financial Management LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter worth $25,000. Purpose Unlimited Inc. purchased a new position in Abbott Laboratories in the fourth quarter valued at $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories during the 4th quarter worth about $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 1.7%

NYSE:ABT opened at $114.11 on Thursday. The company has a market capitalization of $197.45 billion, a PE ratio of 36.93, a price-to-earnings-growth ratio of 2.25 and a beta of 0.59. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The stock has a fifty day simple moving average of $101.66 and a 200-day simple moving average of $100.13. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the prior year, the firm earned $1.26 EPS. Abbott Laboratories’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories’s payout ratio is 81.55%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ABT. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a report on Thursday, August 13th. JPMorgan Chase & Co. increased their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. UBS Group reduced their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Citigroup raised their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Finally, TD Cowen boosted their target price on Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first U.S. wearable designed to continuously monitor both glucose and ketone levels. The device is intended to help detect rising ketones associated with diabetic ketoacidosis and integrates with Abbott’s Libre app, digital-health ecosystem and compatible automated insulin-delivery systems. The approval strengthens Abbott’s continuous glucose-monitoring franchise and could expand its addressable market. Reuters FDA authorization article
• Positive Sentiment: TD Cowen raised its price target for ABT from $115 to $135 and maintained a “buy” rating, implying approximately 18% upside from the referenced $114.11 level. The target increase reflects confidence in Abbott’s growth prospects and valuation relative to peers. Benzinga analyst price target report
• Neutral Sentiment: Industry forecasts identify Abbott as a participant in expanding atrial-fibrillation treatment and device markets, particularly pulsed-field ablation, mapping catheters and left-atrial-appendage closure. These reports point to long-term opportunity but do not provide new Abbott-specific financial guidance. Atrial fibrillation treatment devices market report
• Negative Sentiment: Abbott agreed to pay $670 million to settle claims that its specialized premature-infant formula contributed to necrotizing enterocolitis. The settlement removes some litigation uncertainty but highlights continuing legal and financial risks. Abbott formula claims settlement article

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.